Plasminogen activator inhibitor-1 and type 2 diabetes: a systematic review and meta-analysis of observational studies
dc.contributor.author | Yarmolinsky, James | pt_BR |
dc.contributor.author | Barbieri, Natália Bordin | pt_BR |
dc.contributor.author | Weinmann, Tobias | pt_BR |
dc.contributor.author | Ziegelmann, Patricia Klarmann | pt_BR |
dc.contributor.author | Duncan, Bruce Bartholow | pt_BR |
dc.contributor.author | Schmidt, Maria Inês | pt_BR |
dc.date.accessioned | 2021-08-12T04:43:48Z | pt_BR |
dc.date.issued | 2016 | pt_BR |
dc.identifier.issn | 2045-2322 | pt_BR |
dc.identifier.uri | http://hdl.handle.net/10183/225577 | pt_BR |
dc.description.abstract | An emerging body of evidence has implicated plasminogen activator inhibitor-1 (PAI-1) in the development of type 2 diabetes (T2D), though findings have not always been consistent. We systematically reviewed epidemiological studies examining the association of PAI-1 with T2D. EMBASE, PubMed, Web of Science, and the Cochrane Library were searched to identify studies for inclusion. Fifty-two studies (44 cross-sectional with 47 unique analytical comparisons and 8 prospective) were included. In pooled random-effects analyses of prospective studies, a comparison of the top third vs. bottom third of baseline PAI-1 values generated a RR of T2D of 1.67 (95% CI 1.28–2.18) with moderate heterogeneity (I2=38%). Additionally, of 47 cross-sectional comparisons, 34(72%) reported significantly elevated PAI-1 among diabetes cases versus controls, 2(4%) reported significantly elevated PAI-1 among controls, and 11(24%) reported null effects. Results from pooled analyses of prospective studies did not differ substantially by study design, length of follow-up, adjustment for various putative confounding factors, or study quality, and were robust to sensitivity analyses. Findings from this systematic review of the available epidemiological literature support a link between PAI-1 and T2D, independent of established diabetes risk factors. Given the moderate size of the association and heterogeneity across studies, future prospective studies are warranted. | en |
dc.format.mimetype | application/pdf | pt_BR |
dc.language.iso | eng | pt_BR |
dc.relation.ispartof | Scientific Reports [recurso eletrônico]. London. Vol. 6, Artigo 17714 (2016), [13] p. | pt_BR |
dc.rights | Open Access | en |
dc.subject | Estatística médica | pt_BR |
dc.title | Plasminogen activator inhibitor-1 and type 2 diabetes: a systematic review and meta-analysis of observational studies | pt_BR |
dc.type | Artigo de periódico | pt_BR |
dc.identifier.nrb | 001007837 | pt_BR |
dc.type.origin | Estrangeiro | pt_BR |
Este item está licenciado na Creative Commons License
-
Artigos de Periódicos (39320)Ciências Exatas e da Terra (5974)